ALERT: Halper Sadeh LLP Is Investigating the Following Mergers; Shareholders are Encouraged to Contact the Firm

Dienstag, 15.09.20 19:35
Tafel mit Kursen
Bildquelle: fotolia.com


PR Newswire





NEW YORK, Sept. 15, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating:



Rosetta Stone Inc. (NYSE: RST)concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Cambium Learning Group for $30 per share. To learn more about your legal rights and options, visit: https://halpersadeh.com/actions/rosetta-stone-inc-rst-stock-merger-cambium.

Cellular Biomedicine Group, Inc. (NASDAQ: CBMG)concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to a consortium that includes members of Cellular Biomedicine management and several entities. Under the terms of the merger, Cellular Biomedicine stockholders (excluding certain parties) will receive $19.75 in cash for each outstanding share of common stock held immediately prior to the effective time of the merger. To learn more about your legal rights and options, visit: https://halpersadeh.com/actions/cellular-biomedicine-group-inc-cbmg-stock-merger

Immunomedics, Inc. (NASDAQ: IMMU) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Gilead Sciences, Inc. for $88.00 per share. To learn more about your legal rights and options, visit: https://halpersadeh.com/actions/immunomedics-merger-stock-gilead.

Proteostasis Therapeutics, Inc. (NASDAQ: PTI) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with Yumanity Therapeutics. Under the terms of the merger agreement, Proteostasis will acquire all outstanding shares of Yumanity in exchange for newly-issued shares of Proteostasis common stock, with existing Proteostasis shareholders expected to own approximately 32.5% of the combined company. To learn more about your legal rights and options, visit: https://halpersadeh.com/actions/proteostasis-therapeutics-inc-pti-yumanity-stock-merger.



Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.

Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email sadeh@halpersadeh.com or zhalper@halpersadeh.com.

Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Halper Sadeh LLP

Daniel Sadeh, Esq.

Zachary Halper, Esq.

(212) 763-0060

sadeh@halpersadeh.com 

zhalper@halpersadeh.com  

https://www.halpersadeh.com 





Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/alert-halper-sadeh-llp-is-investigating-the-following-mergers-shareholders-are-encouraged-to-contact-the-firm-301131474.html

SOURCE Halper Sadeh LLP





Quelle: PR Newswire




Hier geht's zur Aktien-Startseite

News und Analysen

Aktien New York: Zarte Erholung von Vortagesverlusten

NEW YORK (dpa-AFX) - Nach dem neuerlichen Kurseinbruch zur Wochenmitte haben die US-Aktienmärkte am Donnerstag einen Erholungsversuch gestartet. Vor allem die am Vortag unter die Räder ...weiterlesen

Seite: 1 | 2 | 3 | 4 | 5 | 6 | ... | 15767 ►

Titel aus dieser Meldung

Datum :
24.09.20
72,94 EUR
-0,11 %
Datum :
24.09.20
25,40 EUR
0,00 %
Datum :
24.09.20
15,50 EUR
0,00 %

Value oder Growth? Eine Frage so alt wie die Börse

Value oder Growth? Eine Frage so alt wie die Börse
Die Frage, ob es sinnvoller ist, auf Value- oder auf Growth-Titel zu setzen, ist beinahe so alt wie die Börse selbst. Dabei sind mit der Bezeichnung „Value“ bewährte Unternehmen gemeint, deren Buchwert idealerweise aktuell möglichst niedrig bewertet wird.
© 1994-2020 by boerse.de - Quelle für Kurse und Daten: ARIVA.DE AG - boerse.de übernimmt keine Gewähr